By: Allison DeAngelis
Medicines for brittle bones and breakages are grabbing the attention of the pharma industry, which has been incentivized by a long-awaited regulatory change.
Allison DeAngelis is a reporter at STAT, specializing in biotech, biopharma startups, and venture capital. She covers a range of topics within medicine and healthcare, including oncology, pharmaceutical manufacturing, and immunotherapy, while also co-hosting the weekly biotech podcast, The Readout Loud. Allison's work has been featured in The Boston Globe, STAT News, and RamaOnHealthcare, highlighting her expertise in the pharmaceutical industry and emerging medical trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Allison Deangelis focuses on the healthcare and pharmaceutical industry, particularly biotechnology. Her articles often include press releases, private sector announcements, data citations, and expert commentary.
To effectively reach out to Allison Deangelis, consider providing insights or access to individuals with expertise in cutting-edge biotechnological developments such as gene therapy, novel drug discoveries for conditions like obesity or cancer treatment. Pitches could also involve exclusive interviews with key figures in startups and established companies within the biotech space.
As Allison's geographic focus is not specified but her coverage seems international in nature due to its emphasis on major industry events and global players within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .